Suchergebnisse - "Dudnik, Elizabeth"

PubPharm (5)

1

dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50

enthalten in: Clinical lung cancer | 2022

von Holtzman, L. | Moskovitz, M. | Urban, D. | +10

2

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50% : real-world data

enthalten in: Oncoimmunology | 2021

von Dudnik, E. | Moskovitz, M. | Rottenberg, Y. | +11

3

Can Ipilimumab restore immune response in advanced NSCLC after progression on anti-PD-1/PD-L1 agents?

enthalten in: Thoracic cancer | 2020

von Sternschuss, M. | Peled, N. | Allen, A. | +6

4

Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC) : Outcomes with immune check-point inhibitors (ICPi)

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2018

von Dudnik, E. | Bshara, E. | Grubstein, A. | +10

5

BRAF Mutant Lung Cancer : Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2018

von Dudnik, E. | Peled, N. | Nechushtan, H. | +17

CommentIn: J Thorac Oncol. 2018 Aug;13(8):1055-1057. - PMID 30056857

1
[1]